➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Express Scripts
Boehringer Ingelheim

Last Updated: July 26, 2021

DrugPatentWatch Database Preview

Details for Patent: 8,784,878

Email this page to a colleague

« Back to Dashboard

Which drugs does patent 8,784,878 protect, and when does it expire?

Patent 8,784,878 protects AXIRON and is included in one NDA.

This patent has eighteen patent family members in eleven countries.

Summary for Patent: 8,784,878
Title:Transdermal delivery rate control using amorphous pharmaceutical compositions
Abstract: A pharmaceutical composition for transdermal delivery comprising one or more physiologically active agents; one or more dermal penetration enhancers; and a volatile pharmaceutically acceptable carrier comprising a volatile solvent; and wherein the physiologically active agent and dermal penetration enhancer form an amorphous deposit upon evaporation of the volatile carrier, said amorphous deposit forming a reservoir within the stratum corneum; and (A) wherein the composition has a release rate profile of physiologically active agent so as to provide a ratio of the maximum concentration (C.sub.max) to the average concentration (C.sub.avg) for the physiologically active agent over the dosage interval within the range of 1 to 10.
Inventor(s): Morgan; Timothy Matthias (Carlton North, AU), Wilkins; Nina Frances (Kensington, AU), Klose; Kathryn Traci-Jane (Bonreach, AU), Finnin; Barrie Charles (Toorak, AU), Reed; Barry Leonard (Essendon, AU)
Assignee: Acrux DDS Pty Ltc. (West Melbourne, Victoria, AU)
Application Number:13/710,761
Patent Claim Types:
see list of patent claims
Composition; Delivery; Use;

Drugs Protected by US Patent 8,784,878

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Eli Lilly And Co AXIRON testosterone SOLUTION, METERED;TRANSDERMAL 022504-001 Nov 23, 2010 DISCN Yes No ⤷  Free Forever Trial ⤷  Free Forever Trial Y A METHOD OF TRANSDERMALLY DELIVERING TESTOSTERONE ⤷  Free Forever Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 8,784,878

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Australia 2003240301 ⤷  Free Forever Trial
Brazil 0312007 ⤷  Free Forever Trial
Brazil PI0312007 ⤷  Free Forever Trial
Canada 2489865 ⤷  Free Forever Trial
Eurasian Patent Organization 009024 ⤷  Free Forever Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.